Indivior Pharmaceuticals, Inc. Earnings Per Share (Basic)
Indivior Pharmaceuticals, Inc. (SUPN) reported Earnings Per Share (Basic) of $1.02 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was $1.02, a 580.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was $0.71, a 86.84% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $0.82, a 389.60% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.34, a 112.50% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was $1.68, a 3260.00% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was $0.05.
- Indivior Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$0.92.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.02 10-Q · filed 2026-08-03 | $1.73 10-Q · filed 2026-08-03 | $2.55 derived: net income ÷ weighted average shares · filed 2026-08-03 | $2.88 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2026-03-31 | $0.71 10-Q · filed 2026-04-30 | $1.53 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.87 derived: net income ÷ weighted average shares · filed 2026-08-03 | $2.01 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-12-31 | $0.82 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.15 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.30 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.68 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.34 10-Q · filed 2025-10-30 | $0.48 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.87 10-Q · filed 2025-10-30 | $1.02 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-06-30 | $0.15 10-Q · filed 2026-08-03 | $0.53 10-Q · filed 2026-08-03 | $0.69 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.85 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-03-31 | $0.38 10-Q · filed 2026-04-30 | $0.54 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.71 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2024-12-31 | $0.17 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.33 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.05 10-K · filed 2026-02-26 | $0.02 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.16 10-Q · filed 2025-10-30 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.11 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$0.72 10-Q · filed 2025-07-31 | -$0.27 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $0.45 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$0.92 10-K · filed 2026-02-26 | -$0.94 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$0.30 10-Q · filed 2025-10-30 | -$0.32 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |